Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 9/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491428 | 1.00 | LMNA (0.50) | LMNAPDE4AMGLLMEN1KMT2A | |
| SCHEMBL22491574 | 0.87 | PDE4D (0.46) | LMNAPDE4AMGLLALDH1A1PDE4D | |
| SCHEMBL22773295 | 0.87 | PDE4D (0.46) | LMNAPDE4AMGLLALDH1A1PDE4D | |
| SCHEMBL22773261 | 0.86 | MMP13 (0.49) | LMNAPDE4AMEN1KMT2AALDH1A1 | |
| SCHEMBL22491429 | 0.83 | KDM4E (0.41) | LMNAMGLLMEN1KMT2AALDH1A1 | |
| SCHEMBL22491592 | 0.83 | KDM4E (0.41) | LMNAMGLLMEN1KMT2AALDH1A1 | |
| SCHEMBL21381630 | 0.78 | SLC6A4 (0.47) | PDE4AKMT2APDE4BPDE4CPDE4D | |
| SCHEMBL29734316 | 0.78 | SLC6A4 (0.47) | PDE4AKMT2APDE4BPDE4CPDE4D | |
| SCHEMBL23211847 | 0.77 | MGLL (0.64) | MGLL | |
| SCHEMBL30149618 | 0.77 | MGLL (0.64) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | LMNA 16/4885PDE4A 2507/4885MGLL 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.